Target type: molecularfunction
Binding to a DED domain (death effector domain) of a protein, a homotypic protein interaction module composed of a bundle of six alpha-helices that is related in structure to the death domain (DD). [GOC:ecd, InterPro:IPR001875]
Death effector domain (DED) binding is a crucial molecular interaction that plays a pivotal role in the regulation of apoptosis, a programmed cell death process essential for maintaining cellular homeostasis. DEDs are conserved protein-protein interaction domains found in a variety of proteins involved in apoptosis signaling pathways. These domains facilitate the assembly of protein complexes, which in turn orchestrate the execution of the apoptotic program. DED-containing proteins can interact with each other through their DEDs, forming homo- or hetero-dimers or even larger oligomers. This interaction is highly specific, ensuring that the correct proteins assemble into functional complexes. The formation of these complexes triggers a cascade of events, culminating in the activation of caspases, a family of cysteine proteases that execute the apoptotic program by cleaving specific cellular substrates. DED-mediated interactions are critical for the proper activation and regulation of caspases, ensuring that apoptosis is initiated only when necessary and proceeds in a controlled manner. Moreover, DED binding contributes to the precise localization of apoptotic signaling components within cells, enabling efficient and targeted execution of the apoptotic program. This intricate interplay of DED-mediated interactions underlines the critical role of DED binding in orchestrating the complex and tightly regulated process of apoptosis.'
"
Protein | Definition | Taxonomy |
---|---|---|
Caspase-10 | A caspase-10 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q92851] | Homo sapiens (human) |
Caspase-8 | A caspase-8 that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
3,3',4,5'-tetrahydroxystilbene | stilbenoid | ||
isoquinoline-1,3,4-trione | isoquinoline-1,3,4-trione: structure in first source | ||
n-methylisatin | N-methylisatin: structure given in first source | ||
2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-benzoic acid | 2,2'-((3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl)diimino)bis-benzoic acid: structure given in first source | ||
stictic acid | stictic acid: antioxidant from lichen, Usnea articulata; structure in first source | aromatic ether | |
pralnacasan | pralnacasan: NSAID, ICE inhibitor & metastasis inhibitor; RN & structure in first source | ||
1,3(2h,4h)-isoquinolinedione | 1,3(2H,4H)-isoquinolinedione: structure in first source | ||
acetyl-aspartyl-glutamyl-valyl-aspartal | Ac-Asp-Glu-Val-Asp-H : A tetrapeptide consisting of two L-aspartic acid residues, an L-glutamyl residue and an L-valine residue with an acetyl group at the N-terminal and with the C-terminal carboxy group reduced to an aldehyde. It is an inhibitor of caspase-3/7. acetyl-aspartyl-glutamyl-valyl-aspartal: a capase inhibitor | tetrapeptide | protease inhibitor |
1,6-dimethyl-3-(2-pyridinyl)pyrimido[5,4-e][1,2,4]triazine-5,7-dione | pyrimidotriazine | ||
1,6-dimethyl-3-propylpyrimido[5,4-e][1,2,4]triazine-5,7-dione | pyrimidotriazine | ||
5-Nitroisatin | indoles | anticoronaviral agent | |
n-acetyltyrosyl-valyl-alanyl-aspartyl aldehyde | |||
benzyloxycarbonyl-phe-ala-fluormethylketone | cathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1). | ||
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone | |||
grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source | ||
MK-8353 | MK-8353 : A member of the class of indazoles that is 1H-indazole substituted by a 6-(propan-2-yloxy)pyridin-3-yl group at position 3 and by a {[(3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)pyrrolidin-3-yl]carbonyl}amino group at position 5. It is a potent and selective inhibitor of ERK1 and ERK2 in vitro (IC50 values of 23.0 nM and 8.8 nM, respectively). The drug is being developed by Merck Sharp & Dohme and is currently in clinical development for the treatment of advanced/metastatic solid tumors. MK-8353: ERK inhibitor used in oncology | aromatic ether; dihydropyridine; indazoles; methyl sulfide; N-alkylpyrrolidine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; triazoles | antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor |